Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 16/20 | 0.72 |
| ▸ | JAK2 | O60674 | 11/20 | 0.71 |
| ▸ | JAK3 | P52333 | 3/20 | 0.71 |
| ▸ | TYK2 | P29597 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2241118 | 0.84 | JAK1 (1.00) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL2238639 | 0.83 | JAK1 (1.00) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL217727 | 0.83 | JAK2 (1.00) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL2237921 | 0.82 | JAK2 (1.00) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL216776 | 0.81 | JAK1 (1.00) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL2237498 | 0.79 | JAK1 (1.00) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL13031528 | 0.78 | JAK1 (0.69) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL219962 | 0.78 | JAK1 (1.00) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL2240406 | 0.78 | JAK1 (1.00) | JAK1JAK2JAK3 | |
| SCHEMBL7960602 | 0.78 | JAK2 (1.00) | JAK1JAK2JAK3TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190260-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ALFASIGMA S.P.A. (IT) | 2011-08-04 | — | — | US | disclosed |
| WO-2010010190-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190260-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | TRAF6, IL6, TLR6 | JAK1 84/4885JAK2 174/4885JAK3 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.